BGI
APGE icon

B Group Inc’s Apogee Therapeutics APGE Stock Holding History

B Group Inc’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$631K Sell
7,500
-12,500
-63% -$908K 0.47% 17
2025
Q4 		$1.51M Sell
20,000
-15,000
-43% -$945K 1.11% 15
2025
Q3 		$1.39M Hold
35,000
– – 1.02% 17
2025
Q2 		$1.52M Buy
35,000
+5,000
+17% +$190K 1.17% 14
2025
Q1 		$1.12M Buy
30,000
+15,000
+100% +$580K 0.96% 15
2024
Q4 		$680K Buy
+15,000
New +$765K 0.42% 14

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

B Group Inc's APGE Position: Q1 2026 in Review

B Group Inc reduced its Apogee Therapeutics (APGE) stake by 63% in Q1 2026, selling an estimated $908K and leaving 7,500 shares worth $631K. The position accounts for 0.47% of the portfolio, ranked #17.

B Group Inc first reported a position in APGE in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.52M in Q2 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • B Group Inc held 7,500 shares of Apogee Therapeutics worth $631K as of Q1 2026.
  • B Group Inc sold 12,500 Apogee Therapeutics shares in Q1 2026, an estimated $908K.
  • Apogee Therapeutics made up 0.47% of B Group Inc's portfolio in Q1 2026, its #17 holding.
  • B Group Inc first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • B Group Inc's Apogee Therapeutics position peaked at $1.52M in Q2 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.